Index Options
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalBreaking Down Veracyte: 7 Analysts Share Their Views
7 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Veracyte and provided 12-month price targets. The average target is $44.71, accompanied by a high estimate of $51.00 and a low estimate of $37.00. A decline of 5.22% from the prior average price target is evident in the current average.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Veracyte among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Lowers | Buy | $41.00 | $51.00 |
| Subbu Nambi | Guggenheim | Lowers | Buy | $37.00 | $45.00 |
| Mason Carrico | Stephens & Co. | Maintains | Overweight | $45.00 | $45.00 |
| John Wilkin | Craig-Hallum | Announces | Buy | $45.00 | - |
| Lu Li | UBS | Raises | Buy | $49.00 | $46.00 |
| Subbu Nambi | Guggenheim | Maintains | Buy | $45.00 | $45.00 |
| Mike Matson | Needham | Maintains | Buy | $51.00 | $51.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veracyte. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Veracyte's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veracyte's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Veracyte analyst ratings.
Discovering Veracyte: A Closer Look
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Veracyte's Economic Impact: An Analysis
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Veracyte showcased positive performance, achieving a revenue growth rate of 20.81% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.31%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Veracyte's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.43% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Veracyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.